ZA882717B - 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors - Google Patents

17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors

Info

Publication number
ZA882717B
ZA882717B ZA882717A ZA882717A ZA882717B ZA 882717 B ZA882717 B ZA 882717B ZA 882717 A ZA882717 A ZA 882717A ZA 882717 A ZA882717 A ZA 882717A ZA 882717 B ZA882717 B ZA 882717B
Authority
ZA
South Africa
Prior art keywords
androst
cyclopropylamino
17beta
3beta
related compounds
Prior art date
Application number
ZA882717A
Other languages
English (en)
Inventor
R. Angelastro Michael
R. Blohm Thomas
Original Assignee
Merrell Dow Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc. filed Critical Merrell Dow Pharmaceuticals Inc.
Publication of ZA882717B publication Critical patent/ZA882717B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
ZA882717A 1987-04-22 1988-04-18 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors ZA882717B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4117287A 1987-04-22 1987-04-22

Publications (1)

Publication Number Publication Date
ZA882717B true ZA882717B (en) 1988-10-17

Family

ID=21915133

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA882717A ZA882717B (en) 1987-04-22 1988-04-18 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors

Country Status (19)

Country Link
EP (1) EP0288053B1 (xx)
JP (1) JP2711672B2 (xx)
KR (1) KR960015037B1 (xx)
CN (1) CN88102176A (xx)
AT (1) ATE67211T1 (xx)
AU (1) AU606677B2 (xx)
CA (1) CA1326234C (xx)
DE (1) DE3864725D1 (xx)
DK (1) DK217588A (xx)
ES (1) ES2038712T3 (xx)
FI (1) FI88397C (xx)
GR (1) GR3002713T3 (xx)
HU (1) HU198511B (xx)
IL (1) IL86139A (xx)
NO (1) NO169346C (xx)
NZ (1) NZ224288A (xx)
PH (1) PH24090A (xx)
PT (1) PT87294B (xx)
ZA (1) ZA882717B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US4954488A (en) * 1989-06-14 1990-09-04 Merrell Dow Pharmaceuticals Inc. Method of treating hyperaldosteronism using 17β-cyclopropylaminoandrostene derivatives
US4966898A (en) * 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5256408A (en) * 1990-06-12 1993-10-26 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5209926A (en) * 1990-06-12 1993-05-11 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5252319A (en) * 1990-06-12 1993-10-12 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
GB2265624B (en) * 1992-03-31 1995-04-19 British Tech Group 17-substituted steroids useful in cancer treatment
US5486511A (en) * 1993-05-25 1996-01-23 Merrell Dow Pharmaceuticals Inc. 4-amino-17β-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17β-(cyclopropylamino)androst-4-en-3-one and related compounds as C17-20 lyase and 5α-reductase
ES2260303T3 (es) 2000-11-17 2006-11-01 Takeda Pharmaceutical Company Limited Derivados de imidazol, metodo para su produccion, y su uso.
US6960586B2 (en) 2000-11-20 2005-11-01 Takeda Pharmaceutical Company Limited Imidazole derivatives, process for their preparation and their use
US7067537B2 (en) 2000-12-08 2006-06-27 Takeda Pharmaceutical Company Limited Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof
ES2475945T3 (es) 2009-06-26 2014-07-11 Novartis Ag Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
AU2011285724B2 (en) 2010-08-04 2015-01-22 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
CN103108871B (zh) 2010-09-16 2014-09-10 诺华股份有限公司 17α-羟化酶/C17,20-裂合酶抑制剂
BR112013027395A2 (pt) 2011-04-28 2017-01-17 Novartis Ag inibidores de 17alfa-hidroxilase/c17,20-liase
WO2014158875A1 (en) 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
AU2015314772B2 (en) 2014-09-12 2020-02-27 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
CA3044812A1 (en) 2016-10-24 2018-05-03 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1,4-dione

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL302932A (xx) 1962-12-31
US4891367A (en) * 1987-04-22 1990-01-02 Merrell Dow Pharmaceuticals Inc. 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors

Also Published As

Publication number Publication date
DK217588A (da) 1988-10-23
EP0288053B1 (en) 1991-09-11
GR3002713T3 (en) 1993-01-25
DE3864725D1 (de) 1991-10-17
KR880012633A (ko) 1988-11-28
IL86139A0 (en) 1988-11-15
EP0288053A1 (en) 1988-10-26
NO881746L (no) 1988-10-24
PT87294A (pt) 1988-05-01
JPS63284195A (ja) 1988-11-21
DK217588D0 (da) 1988-04-21
FI88397B (fi) 1993-01-29
AU1471988A (en) 1988-10-27
CA1326234C (en) 1994-01-18
IL86139A (en) 1993-02-21
PH24090A (en) 1990-03-05
NO169346C (no) 1992-06-10
ATE67211T1 (de) 1991-09-15
NO881746D0 (no) 1988-04-21
JP2711672B2 (ja) 1998-02-10
KR960015037B1 (ko) 1996-10-24
HUT47307A (en) 1989-02-28
FI88397C (fi) 1993-05-10
CN88102176A (zh) 1988-11-23
NO169346B (no) 1992-03-02
AU606677B2 (en) 1991-02-14
PT87294B (pt) 1992-08-31
FI881877A0 (fi) 1988-04-21
HU198511B (en) 1989-10-30
ES2038712T3 (es) 1993-08-01
NZ224288A (en) 1989-12-21
FI881877A (fi) 1988-10-23

Similar Documents

Publication Publication Date Title
IL86139A0 (en) 17beta-(cyclopropylimino)androst-5-en-3beta-ol and related compounds useful as c17-20 lyase inhibitors
EP0413270A3 (en) 4-substituted 17beta-(cyclopropylamino)androst-5-en-3beta-ol and related compounds useful as c17-20 lyase inhibitors
PH27549A (en) 4-Substituted 17b- cyclo-propyloxy)androst-5-en-3beta- ol and related compounds useful as c17-20 lyase inhibitors
GB9514451D0 (en) Sustained-release formulation
PH23863A (en) 17b-(cyclopropyloxy)androst-5-en-3b-ol and related compounds useful as c17-20 lyase inhibitors
EP0305181A3 (en) Ethyl-(+)-apovincaminate for treating demyelinization clinical patterns of autoimmune origin
HU911039D0 (en) Process for the production of hydroxymethyl-indolizidine and kynolizidine derivatives